Table II.

Univariate and multivariate logistic regression analyses of rituximab use among those treated with known chemotherapy drugs who were diagnosed after rituximab became available (n =2433).

	Univariate odds ratio (95% CI)	p-Value	Adjusted odds ratio (95% CI)	p-Value
Age at diagnosis (reference =66–70)		0.0543		0.0163
71–75	1.024 (0.819–1.281)	0.8326	1.055 (0.796–1.397)	0.7094
76–80	0.793 (0.631–0.997)	0.0470	0.764 (0.574–1.016)	0.0637
81–84	0.888 (0.673–1.172)	0.4014	0.698 (0.493–0.987)	0.0422
85+	0.726 (0.528–0.999)	0.0492	0.664 (0.444–0.992)	0.0458
Year of diagnosis (reference =2002)		<0.0001		<0.0001
1999	0.014 (0.008–0.024)	<0.0001	0.014 (0.008–0.024)	<0.0001
2000	0.061 (0.047–0.079)	<0.0001	0.054 (0.041–0.072)	<0.0001
2001	0.327 (0.259–0.413)	<0.0001	0.307 (0.241–0.391)	<0.0001
Stage (reference =stage 1)		0.0046		0.0139
Stage 2	1.198 (0.949–1.511)	0.1282	1.220 (0.914–1.628)	0.1766
Stage 3	1.415 (1.100–1.819)	0.0068	1.504 (1.099–2.060)	0.0109
Stage 4	1.478 (1.197–1.826)	0.0003	1.559 (1.192–2.038)	0.0012
ABC use (reference =no)		0.0827		0.0523
Yes	1.269 (0.970–1.660)	0.0827	1.392 (0.997–1.994)	0.0523
Gender (reference = female)		0.1513		0.1360
Male	1.125 (0.958–1.321)	0.1513	1.165 (0.953–1.423)	0.1360
Physician claims comorbidity (reference =0)		0.4797		0.7925
≥1	1.070 (0.887–1.291)	0.4797	1.032 (0.817–1.303)	0.7925
Inpatient claims comorbidity (reference =0)		0.7435		0.6009
≥1	1.043 (0.812–1.340)	0.7435	0.920 (0.673–1.258)	0.6009
B-symptoms (reference =no)		0.3936		0.8832
Yes	0.943 (0.751–1.185)	0.6137	1.065 (0.800–1.419)	0.6657

CI, confidence interval; ABC, anthracycline-based chemotherapy.